Zhuang Li, Zhu Chi, Ma Jincheng, Zhu Dan, Zhu Hengkai, Zhong Siyi, Liu Xiangyan, Wang Zhuoyi, Yang Zhe, Zhang Wu, Ding Ran, Chen Dongsheng, Zheng Shusen
Hepatopancreatobiliary Surgery Department, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Zhejiang, China.
State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co.,Ltd., Nanjing, China.
Heliyon. 2024 Aug 15;10(16):e36405. doi: 10.1016/j.heliyon.2024.e36405. eCollection 2024 Aug 30.
To evaluate the predictive performance of metagenomic next-generation sequencing (mNGS) in identifying and predicting pulmonary infections following liver transplantation and to investigate its association with patient outcomes within the initial four-week post-transplantation period.
We retrospectively analyzed 41 liver transplant patients with suspected pulmonary infections from August 2022 to May 2023. Bronchoalveolar lavage fluid (BALF) samples were collected on the first postoperative day for metagenomic next generation sequencing (mNGS) and culture. The predictive capability of mNGS for subsequent infections was assessed by monitoring inflammatory biomarkers and comparing the detection rates with culture methods. Real-time Polymerase Chain Reaction (Rt-PCR) was used to monitor Human betaherpesvirus 5 (CMV) and Human parvovirus B19 (B19) weekly during a four-week postoperative period. Inflammatory biomarkers and blood coagulation function were evaluated on specific days throughout the first, third, fifth, and during four weeks following surgery. The study was conducted until August 2023 to evaluate the patients' prognostic survival outcome, classifying them into groups based on the mortality and survival.
The analysis included a total of 41 patients, comprising 32 males and 9 females, with an average age of 52 (47, 63) years. Within one week after liver transplantation, there were 7 cases of bacterial infections, 5 cases of fungal infections, 19 cases of mixed infections, 8 cases without any infection, and 2 cases with unidentified pathogen-associated infections. mNGS successfully predicted 39 (72 %) strains of pathogens, while culture-based methods only detected 28 (52 %) strains. Among the 8 patients diagnosed as non-infected, culture methods identified positive results in 4 cases (50 %), whereas mNGS yielded positive results in 7 cases (87.5 %). The detection rates of CMV and B19 by Rt-PCR within 4 weeks after liver transplantation were 61 % and 17 %, respectively (25/41, 7/41) among the patients. During the study period, a total of 9 patients succumbed while 32 patients survived. The death group and the survival group exhibited significant differences in CRP, HGB, and INR levels at specific monitoring time points. The proportion of CMV detection in blood was significantly higher in the death group compared to the surviving group. Elevated CRP level was identified as a prognostic risk factor.
Despite the presence of false positives, mNGS still presents a potential advantage in predicting pulmonary infection pathogens following liver transplantation. Furthermore, the levels of CRP and CMV carrier status within four weeks post-surgery exhibit significant associations with patient survival and prognosis.
评估宏基因组下一代测序(mNGS)在肝移植后肺部感染的识别和预测中的性能,并研究其与移植后最初四周内患者预后的关系。
我们回顾性分析了2022年8月至2023年5月期间41例疑似肺部感染的肝移植患者。术后第一天采集支气管肺泡灌洗液(BALF)样本进行宏基因组下一代测序(mNGS)和培养。通过监测炎症生物标志物并将检测率与培养方法进行比较,评估mNGS对后续感染的预测能力。在术后四周内每周使用实时聚合酶链反应(Rt-PCR)监测人β疱疹病毒5(CMV)和人细小病毒B19(B19)。在术后第一、第三、第五天以及术后四周内的特定日期评估炎症生物标志物和凝血功能。该研究持续至2023年8月,以评估患者的预后生存结果,根据死亡率和生存率将他们分组。
分析共纳入41例患者,其中男性32例,女性9例,平均年龄52(47,63)岁。肝移植后一周内,有7例细菌感染、5例真菌感染、19例混合感染、8例无任何感染以及2例病原体不明的相关感染。mNGS成功预测了39(72%)株病原体,而基于培养的方法仅检测到28(52%)株。在8例诊断为未感染的患者中,培养方法在4例(50%)中检测出阳性结果,而mNGS在7例(%)中检测出阳性结果。肝移植后4周内,患者中Rt-PCR检测CMV和B19的阳性率分别为61%和17%(25/41,7/41)。在研究期间,共有9例患者死亡,32例患者存活。死亡组和存活组在特定监测时间点的CRP、HGB和INR水平存在显著差异。死亡组血液中CMV检测比例显著高于存活组。CRP水平升高被确定为预后危险因素。
尽管存在假阳性,mNGS在预测肝移植后肺部感染病原体方面仍具有潜在优势。此外,术后四周内CRP水平和CMV携带状态与患者生存和预后显著相关。